Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
TRNS
Top 10 Correlated ETFs
TRNS
Top 10 Correlated Stocks
TRNS
In the News
Transcat, Inc. to Present at 14th Annual Southwest IDEAS Investor Conference on November 16th in Dallas, TX
ROCHESTER, N.Y.
Transcat, Inc. (TRNS) Q2 2023 Earnings Call Transcript
Transcat, Inc. (NASDAQ:TRNS ) Q2 2023 Results Conference Call November 1, 2022 11:00 AM ET Company Participants Tom Barbato - CFO Lee Rudow - President, CEO and Director Mark Doheny - COO Conference Call Participants Greg Palm - Craig-Hallum Capital Group Gerry Sweeney - ROTH Capital Scott Buck - H.C. Wainwright Ted Jackson - Northland Securities Mitra Ramgopal - Sidoti Operator Greetings and welcome to Transcat, Inc. Second Quarter 2023 Financial Results.
Transcat, Inc. (TRNS) Lags Q2 Earnings Estimates
Transcat, Inc. (TRNS) delivered earnings and revenue surprises of -18.42% and 2.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Transcat Inc (TRNS) CEO Lee Rudow on Q1 2023 Results - Earnings Call Transcript
Transcat Inc (NASDAQ:TRNS ) Q1 2023 Earnings Conference Call August 2, 2022 11:00 AM ET Company Participants Tom Barbato - SVP of Finance Lee Rudow - President, CEO and Director Mark Doheny - VP of Finance, CFO and Treasurer Conference Call Participants Greg Palm - Craig-Hallum Capital Group Scott Buck - H.C. Wainwright Gerry Sweeney - ROTH Capital Operator Greetings, and welcome to Transcat, Inc. First Quarter 2023 Financial Results Conference Call.
Transcat, Inc. (TRNS) Surpasses Q1 Earnings and Revenue Estimates
Transcat, Inc. (TRNS) delivered earnings and revenue surprises of 53.85% and 5.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Transcat, Inc. (TRNS) Q1 Earnings Expected to Decline
Transcat, Inc. (TRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Transcat, Inc. (TRNS) CEO Lee Rudow on Q4 2022 Results - Earnings Call Transcript
Transcat, Inc. (NASDAQ:TRNS ) Q4 2022 Earnings Conference Call May 24, 2022 11:00 AM ET Company Participants Thomas Barbato - Senior Vice President of Finance Lee Rudow - President and Chief Executive Officer Mark Doheny - Vice President and Chief Financial Officer Conference Call Participants Gerard Sweeney - ROTH Capital Partners, LLC Gregory Palm - Craig-Hallum Capital Group LLC Mitra Ramgopal - Sidoti & Company, LLC Operator Greetings, and welcome to Transcat Incorporated Fourth Quarter and Full Fiscal Year 2022 Financial Results. At this time, all participants are in a listen-only mode.
Transcat, Inc. (TRNS) Q4 Earnings and Revenues Top Estimates
Transcat, Inc. (TRNS) delivered earnings and revenue surprises of 22.73% and 1.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Transcat (TRNS) Surges 7.6%: Is This an Indication of Further Gains?
Transcat (TRNS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AMOT or TRNS: Which Is the Better Value Stock Right Now?
AMOT vs. TRNS: Which Stock Is the Better Value Option?
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-03-26
| Metric | History | 2018-03-31 | 2019-03-30 | 2020-03-28 | 2021-03-31 | 2022-03-26 |
|---|---|---|---|---|---|---|
| Revenue per share | 21.78 | 22.36 | 23.61 | 23.35 | 27.34 | |
| Net income per share | 0.83 | 0.99 | 1.1 | 1.05 | 1.52 | |
| Operating cash flow per share | 1.39 | 1.75 | 1.58 | 3.18 | 2.35 | |
| Free cash flow per share | 0.56 | 0.77 | 0.68 | 2.29 | 1 | |
| Cash per share | 0.08 | 0.11 | 0.07 | 0.08 | 0.19 | |
| Book value per share | 7.21 | 8.29 | 9.15 | 10.11 | 11.5 | |
| Tangible book value per share | 1.84 | 2.76 | 2.4 | 3.27 | 0.86 | |
| Share holders equity per share | 7.21 | 8.29 | 9.15 | 10.11 | 11.5 | |
| Interest debt per share | 3.36 | 3.06 | 5.22 | 3.85 | 7.82 | |
| Market cap | 117.55M | 178.1M | 198.67M | 371.15M | 573.22M | |
| Enterprise value | 139.82M | 198.32M | 235.35M | 398.11M | 629.47M | |
| P/E ratio | 19.85 | 24.93 | 24.63 | 47.64 | 50.37 | |
| Price to sales ratio | 0.76 | 1.11 | 1.15 | 2.14 | 2.8 | |
| POCF ratio | 11.9 | 14.18 | 17.18 | 15.7 | 32.54 | |
| PFCF ratio | 29.45 | 32.02 | 39.88 | 21.8 | 76.78 | |
| P/B Ratio | 2.29 | 2.99 | 2.96 | 4.94 | 6.65 | |
| PTB ratio | 2.29 | 2.99 | 2.96 | 4.94 | 6.65 | |
| EV to sales | 0.9 | 1.23 | 1.36 | 2.3 | 3.07 | |
| Enterprise value over EBITDA | 9.31 | 11.95 | 13.44 | 21.34 | 26.55 | |
| EV to operating cash flow | 14.16 | 15.79 | 20.36 | 16.84 | 35.73 | |
| EV to free cash flow | 35.02 | 35.65 | 47.24 | 23.39 | 84.31 | |
| Earnings yield | 0.05 | 0.04 | 0.04 | 0.02 | 0.02 | |
| Free cash flow yield | 0.03 | 0.03 | 0.03 | 0.05 | 0.01 | |
| Debt to equity | 0.4 | 0.32 | 0.52 | 0.34 | 0.64 | |
| Debt to assets | 0.47 | 0.43 | 0.48 | 0.43 | 0.52 | |
| Net debt to EBITDA | 1.48 | 1.22 | 2.09 | 1.45 | 2.37 | |
| Current ratio | 1.92 | 2.03 | 2.32 | 1.95 | 2.15 | |
| Interest coverage | 8.37 | 10.29 | 9.69 | 10.15 | 14.84 | |
| Income quality | 1.67 | 1.76 | 1.43 | 3.03 | 1.55 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.08 | 0.08 | 0.08 | 0.1 | 0.12 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.4 | 0.38 | 0.39 | 0.38 | 0.45 | |
| Capex to operating cash flow | -0.6 | -0.56 | -0.57 | -0.28 | -0.58 | |
| Capex to revenue | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 | |
| Capex to depreciation | -0.98 | -1.1 | -0.99 | -0.87 | -1.06 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 11.61 | 13.61 | 15.05 | 15.45 | 19.82 | |
| ROIC | 0.12 | 0.12 | 0.1 | 0.1 | 0.09 | |
| Return on tangible assets | 0.1 | 0.11 | 0.1 | 0.1 | 0.12 | |
| Graham Net | -2.67 | -2.25 | -4.01 | -3.35 | -7.15 | |
| Working capital | 19.36M | 22.86M | 27.54M | 23.79M | 31.99M | |
| Tangible asset value | 13.1M | 19.85M | 17.57M | 24.29M | 6.41M | |
| Net current asset value | -4.96M | -594K | -12.58M | -8.11M | -31.88M | |
| Invested capital | 0.45 | 0.35 | 0.55 | 0.37 | 0.67 | |
| Average receivables | 30.21M | 31.48M | 33.23M | 34.38M | 37.34M | |
| Average payables | 12.91M | 13.42M | 12.11M | 12.28M | 13.22M | |
| Average inventory | 12.14M | 12.97M | 12.91M | 11.64M | 12.17M | |
| Days sales outstanding | 61.28 | 64.85 | 67.65 | 72.39 | 71.76 | |
| Days payables outstanding | 41.97 | 43.76 | 33.38 | 35.22 | 35.3 | |
| Days of inventory on hand | 39.23 | 42.95 | 39.62 | 33.39 | 31.67 | |
| Receivables turnover | 5.96 | 5.63 | 5.4 | 5.04 | 5.09 | |
| Payables turnover | 8.7 | 8.34 | 10.93 | 10.36 | 10.34 | |
| Inventory turnover | 9.3 | 8.5 | 9.21 | 10.93 | 11.53 | |
| ROE | 0.12 | 0.12 | 0.12 | 0.1 | 0.13 | |
| Capex per share | -0.83 | -0.97 | -0.9 | -0.89 | -1.35 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-24 for Q2
| Metric | History | 2021-09-30 | 2021-12-25 | 2022-03-26 | 2022-06-25 | 2022-09-24 |
|---|---|---|---|---|---|---|
| Revenue per share | 6.73 | 6.77 | 7.43 | 7.25 | 7.48 | |
| Net income per share | 0.4 | 0.22 | 0.41 | 0.41 | 0.31 | |
| Operating cash flow per share | 0.73 | 0.65 | 0.7 | 0.27 | 0.42 | |
| Free cash flow per share | 0.38 | 0.37 | 0.13 | -0.05 | 0.11 | |
| Cash per share | 0.34 | 0.37 | 0.19 | 0.06 | 0.12 | |
| Book value per share | 10.79 | 11.03 | 11.46 | 11.88 | 12.23 | |
| Tangible book value per share | 1.14 | 1.63 | 0.85 | 0.91 | 1.5 | |
| Share holders equity per share | 10.79 | 11.03 | 11.46 | 11.88 | 12.23 | |
| Interest debt per share | 6.68 | 6.39 | 7.71 | 8.33 | 8.49 | |
| Market cap | 482.44M | 721.82M | 558.28M | 463.78M | 513.25M | |
| Enterprise value | 529.64M | 766.92M | 614.53M | 525.92M | 575.89M | |
| P/E ratio | 40 | 110.78 | 45.79 | 37.74 | 54.44 | |
| Price to sales ratio | 9.57 | 14.18 | 9.99 | 8.48 | 9.09 | |
| POCF ratio | 88.57 | 148.04 | 106.54 | 227.01 | 160.79 | |
| PFCF ratio | 167.51 | 259.18 | 588.28 | -1.3K | 626.68 | |
| P/B Ratio | 5.97 | 8.71 | 6.48 | 5.18 | 5.56 | |
| PTB ratio | 5.97 | 8.71 | 6.48 | 5.18 | 5.56 | |
| EV to sales | 10.51 | 15.07 | 11 | 9.62 | 10.2 | |
| Enterprise value over EBITDA | 92.61 | 149.53 | 85.55 | 84.21 | 89.93 | |
| EV to operating cash flow | 97.24 | 157.29 | 117.28 | 257.43 | 180.42 | |
| EV to free cash flow | 183.9 | 275.38 | 647.56 | -1.48K | 703.16 | |
| Earnings yield | 0.01 | 0 | 0.01 | 0.01 | 0 | |
| Free cash flow yield | 0.01 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.59 | 0.55 | 0.64 | 0.67 | 0.66 | |
| Debt to assets | 0.49 | 0.49 | 0.52 | 0.51 | 0.51 | |
| Net debt to EBITDA | 8.25 | 8.79 | 7.83 | 9.95 | 9.78 | |
| Current ratio | 2.49 | 2.34 | 2.15 | 2.48 | 2.52 | |
| Interest coverage | 14.31 | 17.36 | 12.14 | 23.1 | 6.75 | |
| Income quality | 1.81 | 2.99 | 1.72 | 0.67 | 1.35 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.12 | 0.12 | 0.12 | 0.12 | 0.13 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.46 | 0.44 | 0.45 | 0.45 | 0.43 | |
| Capex to operating cash flow | -0.47 | -0.43 | -0.82 | -1.17 | -0.74 | |
| Capex to revenue | -0.05 | -0.04 | -0.08 | -0.04 | -0.04 | |
| Capex to depreciation | -1.2 | -0.76 | -1.61 | -0.91 | -0.85 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Graham number | 9.89 | 7.33 | 10.22 | 10.44 | 9.27 | |
| ROIC | 0.03 | 0.02 | 0.03 | 0.02 | 0.02 | |
| Return on tangible assets | 0.04 | 0.02 | 0.03 | 0.03 | 0.02 | |
| Graham Net | -5.64 | -5.65 | -7.13 | -7.39 | -7.25 | |
| Working capital | 32.2M | 32.93M | 31.99M | 35.06M | 37.73M | |
| Tangible asset value | 8.55M | 12.26M | 6.41M | 6.87M | 11.33M | |
| Net current asset value | -23.8M | -21.15M | -31.88M | -33.69M | -31.78M | |
| Invested capital | 0.62 | 0.58 | 0.67 | 0.7 | 0.69 | |
| Average receivables | 37.74M | 36.95M | 39.43M | 38.56M | 39.54M | |
| Average payables | 11.98M | 12.97M | 13.57M | 12.97M | 13.28M | |
| Average inventory | 12.57M | 14.4M | 13.82M | 14.94M | 15.85M | |
| Days sales outstanding | 65.93 | 62.47 | 64.9 | 63.5 | 64.62 | |
| Days payables outstanding | 27.63 | 31.31 | 32.53 | 30.22 | 30.85 | |
| Days of inventory on hand | 25.67 | 33.49 | 29.18 | 34.8 | 38.03 | |
| Receivables turnover | 1.37 | 1.44 | 1.39 | 1.42 | 1.39 | |
| Payables turnover | 3.26 | 2.87 | 2.77 | 2.98 | 2.92 | |
| Inventory turnover | 3.51 | 2.69 | 3.08 | 2.59 | 2.37 | |
| ROE | 0.04 | 0.02 | 0.04 | 0.03 | 0.03 | |
| Capex per share | -0.34 | -0.28 | -0.57 | -0.32 | -0.31 |
Frequently Asked Questions
What is Transcat, Inc. stock symbol ?
Transcat, Inc. is a US stock , located in Rochester of New york and trading under the symbol TRNS
What is Transcat, Inc. stock quote today ?
Transcat, Inc. stock price is $78.91 today.
Is Transcat, Inc. stock public?
Yes, Transcat, Inc. is a publicly traded company.
Company Profile
- Volume Average 34.52K
- Market Capitalization 631.95M
- Employee 812
- CEO Mr. Lee Rudow
- Headquarters Rochester,NEW YORK,US
- IPO Date 1965-07-05
-
Website
https://www.transcat.com 
Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management software that is used to integrate and manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.
